Unadjusted outcome rates (uncapped vs capped dosing) in patients with metastatic cancer
| . | Capped dose . | Uncapped dose . | OR (95% CI) . | P . |
|---|---|---|---|---|
| Patients, n | 31 | 105 | ||
| 15-d outcome, n (%) | ||||
| Recurrent PE | 0 (0) | 0 (0) | — | — |
| Recurrent DVT | 0 (0) | 2 (1.9) | — | >.99 |
| Recurrent VTE | 0 (0) | 2 (1.9) | — | >.99 |
| Major bleeding | 0 (0) | 2 (1.9) | — | >.99 |
| Retroperitoneal | 0 (0) | 1 (0.95) | — | >.99 |
| Menorrhagia | 0 (0) | 1 (0.95) | — | >.99 |
| Death | 0 (0) | 7 (6.7) | — | .351 |
| Cause of death | ||||
| Pulmonary embolism | 0 (0) | 2 (1.9) | — | >.99 |
| Sudden, unexpected | 0 (0) | 1 (0.95) | — | >.99 |
| Ischemic stroke | 0 (0) | 1 (0.95) | — | >.99 |
| Neoplasia | 0 (0) | 3 (2.9) | — | >.99 |
| Composite outcome | 0 (0) | 11 (10.4) | — | .051 |
| . | Capped dose . | Uncapped dose . | OR (95% CI) . | P . |
|---|---|---|---|---|
| Patients, n | 31 | 105 | ||
| 15-d outcome, n (%) | ||||
| Recurrent PE | 0 (0) | 0 (0) | — | — |
| Recurrent DVT | 0 (0) | 2 (1.9) | — | >.99 |
| Recurrent VTE | 0 (0) | 2 (1.9) | — | >.99 |
| Major bleeding | 0 (0) | 2 (1.9) | — | >.99 |
| Retroperitoneal | 0 (0) | 1 (0.95) | — | >.99 |
| Menorrhagia | 0 (0) | 1 (0.95) | — | >.99 |
| Death | 0 (0) | 7 (6.7) | — | .351 |
| Cause of death | ||||
| Pulmonary embolism | 0 (0) | 2 (1.9) | — | >.99 |
| Sudden, unexpected | 0 (0) | 1 (0.95) | — | >.99 |
| Ischemic stroke | 0 (0) | 1 (0.95) | — | >.99 |
| Neoplasia | 0 (0) | 3 (2.9) | — | >.99 |
| Composite outcome | 0 (0) | 11 (10.4) | — | .051 |